This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Jul 2011

EU Agency Issues Warnings over Actos Cancer Risk

The EMA said Takeda Pharmaceutical's diabetes pill Actos should carry new warnings about its possible link to bladder cancer.

Europe's drug regulator has given its support to continued use of Takeda's diabetes medication Actos, but has opted to increase warnings regarding bladder cancer risk.


The move by the European Medicines Agency comes after both France and Germany suspended the use of the medication after new data came to light, indicating an increased risk of bladder cancer in patients using medications containing pioglitazone.


The EMA's Committee for Medicinal Products for Human Use has ruled that medicines containing pioglitazone remain a valid treatment option for sufferers of type 2 diabetes, but added that the risk of bladder cancer could be reduced by appropriate patient selection and exclusion.



Related News